الصفحة الرئيسية>>Signaling Pathways>> Metabolism>> Ferroptosis>>ML-210

ML-210 (Synonyms: DPI10)

رقم الكتالوجGC18705

ML-210 هو مثبط انتقائي وتساهمي للجلوتاثيون بيروكسيديز 4 (GPX4) مع EC50 من 30 نانومتريربط ML-210 بقايا GPX4 selenocysteineML-210 له نشاط مضاد للسرطان

Products are for research use only. Not for human use. We do not sell to patients.

ML-210 التركيب الكيميائي

Cas No.: 1360705-96-9

الحجم السعر المخزون الكميّة
10mM (in 1mL DMSO)
66٫00
متوفر
1mg
29٫00
متوفر
5mg
63٫00
متوفر
10mg
112٫00
متوفر
50mg
336٫00
متوفر

Tel:(909) 407-4943 Email: sales@glpbio.com

مراجعات العميل

بناء على آراء العملاء.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Product has been cited by 1 publications

Description Chemical Properties Product Documents Related Products

ML-210 is an inhibitor of glutathione peroxidase 4 (GPX4).[1] It reduces viability of mesenchymal-state KP4 cells, an effect that can be blocked by the arachidonic acid lipoxygenase inhibitors PD 146176 and zileuton. It is also selectively lethal to mutant RAS oncogene-expressing cells (IC50s = 71 and 272 nM in HRASG12V-expressing and wild-type RAS-expressing BJeH cells, respectively).[2]

Reference:
[1]. Viswanathan, V.S., Ryan, M.J., Dhruv, H.D., et al. Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway. Nature 547(7664), 453-457 (2017).
[2]. Weïwer, M., Bittker, J.A., Lewis, T.A., et al. Development of small-molecule probes that selectively kill cells induced to express mutant RAS. Bioorg. Med. Chem. Lett. 22(4), 1822-1826 (2012).

مراجعات

Review for ML-210

Average Rating: 5 ★★★★★ (Based on Reviews and 4 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for ML-210

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.